Alf E. A. Lindberg
Directeur Général chez Nobel Web AB
Profil
Alf E.
A.
Lindberg is currently the Chief Executive Officer at Nobel Web AB.
He also holds director positions at Catella Healthcare AB, Viscogel AB, Inter Ikea Life Sciences AB, Source Bioscience Healthcare, and Iskandu Ltd.
In the past, Lindberg served as a director at AVANT Immunotherapeutics, Inc. from 2005 to 2008, and as a non-executive director at Eurocine Vaccines AB, Proteome Sciences Plc, Pharmexa A, Novavax AB, Lytix Biopharma AS, and Xbrane Biopharma AB.
He was also the Vice President of Research & Development at Sanofi Pasteur, Inc. Lindberg's education includes a doctorate degree from Karolinska Institutet in 1971.
Postes actifs de Alf E. A. Lindberg
| Sociétés | Poste | Début |
|---|---|---|
| Nobel Web AB | Directeur Général | - |
Catella Healthcare AB
 Catella Healthcare AB Investment ManagersFinance Part of Catella AB, Catella Healthcare AB is an alternative investment manager. The company is based in Stockholm, Sweden. | Directeur/Membre du Conseil | - |
| Viscogel AB | Directeur/Membre du Conseil | - |
| Inter Ikea Life Sciences AB | Directeur/Membre du Conseil | - |
Source Bioscience Healthcare
 Source Bioscience Healthcare Medical SpecialtiesHealth Technology Source Bioscience Healthcare manufactures and supplies analytical testing laboratory products and provides laboratory services. The private company is based in Nottingham, UK. | Directeur/Membre du Conseil | - |
Iskandu Ltd.
 Iskandu Ltd. Medical/Nursing ServicesHealth Services Iskandu Ltd. provides health and fitness services. The company is headquartered in Birmingham, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alf E. A. Lindberg
| Sociétés | Poste | Fin |
|---|---|---|
| LYTIX BIOPHARMA | Directeur/Membre du Conseil | 11/06/2014 |
| PROTEOME SCIENCES PLC | Directeur/Membre du Conseil | 22/12/2010 |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Directeur/Membre du Conseil | 16/06/2009 |
| ░░░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Formation de Alf E. A. Lindberg
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| EUROCINE VACCINES AB | Health Technology |
| PROTEOME SCIENCES PLC | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| XBRANE BIOPHARMA AB | Health Technology |
| Entreprise privées | 11 |
|---|---|
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Sanofi Pasteur, Inc.
 Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. | Health Technology |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
Novavax AB
 Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Health Technology |
Catella Healthcare AB
Catella Healthcare AB Investment ManagersFinance Part of Catella AB, Catella Healthcare AB is an alternative investment manager. The company is based in Stockholm, Sweden. | Finance |
| Nobel Web AB | |
| Wyeth-Lederle Laboratories | |
| Viscogel AB | |
| Inter Ikea Life Sciences AB | |
Source Bioscience Healthcare
Source Bioscience Healthcare Medical SpecialtiesHealth Technology Source Bioscience Healthcare manufactures and supplies analytical testing laboratory products and provides laboratory services. The private company is based in Nottingham, UK. | Health Technology |
Iskandu Ltd.
Iskandu Ltd. Medical/Nursing ServicesHealth Services Iskandu Ltd. provides health and fitness services. The company is headquartered in Birmingham, the United Kingdom. | Health Services |